体外药敏实验对卵巢癌个体化化疗的疗效分析
|
摘要
目的比较卵巢癌体外药敏试验化疗方案与经验化疗方案的疗效差异。方法采用ATP-TCA法对75例卵巢癌肿瘤新鲜组织标本进行体外培养及肿瘤药物敏感性试验,选用临床常用的8种化疗药物进行测试,将化疗效果与经验化疗方案进行对比,并随访患者比较两者的差异。结果体外药敏试验结果提示75例卵巢癌标本对常见化疗药敏感性高;根据药敏结果选用中、高度敏感药物进行化疗,总有效率为77. 33%,高于对照组。药敏组无进展生存期与中位生存期分别为20. 72月及30. 30月,均长于对照组,3年生存率也高于对照组,差异有统计学意义(P <0. 05)。结论根据肿瘤药物敏感试验选用的化疗药物能有效治疗卵巢癌,对患者的个体化化疗具有一定的指导意义。
Objective To investigate the differences between in vitro chemo-sensitivity test program and empirical treatments in the treatment of patients with ovarian cancer.Methods The sensitivity of chemo-sensitivity test of 8 common used chemotherapeutic drugs on 75 ovarian cancer samples was examined by using ATP-TCA methods.The curative effects between the in vitro chemo-sensitivity test program and empirical treatment were compared and clinical outcome were followed. Results It was showed that the ovarian cancer samples had high chemo-sensitivity to the common used chemotherapeutic drugs. The medium and highly sensitive drugs were chosen for chemotherapy according to drug sensitivity results. The total effectiveness rates in the chemo-sensitivity test group were77. 33%,which was significantly higher than that in the empirical treatment group. The PFS and OS were 20. 72 months and 30. 30 months,respectively in the chemo-sensitivity test group,which were longer than that in the empirical treatment group.Moreover,the 3-year survival rate in the chemo-sensitivity test group was higher than that in the empirical treatment group( P < 0. 05).Conclusion Chemo-sensitivity testing may provide a practical method for testing new regimens before clinical trials in ovarian cancer patients.It may be helpful to determine the individualized chemotherapy.
Objective To investigate the differences between in vitro chemo-sensitivity test program and empirical treatments in the treatment of patients with ovarian cancer.Methods The sensitivity of chemo-sensitivity test of 8 common used chemotherapeutic drugs on 75 ovarian cancer samples was examined by using ATP-TCA methods.The curative effects between the in vitro chemo-sensitivity test program and empirical treatment were compared and clinical outcome were followed. Results It was showed that the ovarian cancer samples had high chemo-sensitivity to the common used chemotherapeutic drugs. The medium and highly sensitive drugs were chosen for chemotherapy according to drug sensitivity results. The total effectiveness rates in the chemo-sensitivity test group were77. 33%,which was significantly higher than that in the empirical treatment group. The PFS and OS were 20. 72 months and 30. 30 months,respectively in the chemo-sensitivity test group,which were longer than that in the empirical treatment group.Moreover,the 3-year survival rate in the chemo-sensitivity test group was higher than that in the empirical treatment group( P < 0. 05).Conclusion Chemo-sensitivity testing may provide a practical method for testing new regimens before clinical trials in ovarian cancer patients.It may be helpful to determine the individualized chemotherapy.
引文
[1]Tatar B,Boyraz G,Selcuk I,et al.In vitro chemosensitivity in ovarian carcinoma:Comparison of three leading assays[J]. Journal of The Turkish-German Gynecological Association,2016,17(1):35-40.
[2]Van de laar R,Zusterzeel PL,Vangorp TA,et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer(SOCceR trial):a multicenter randomised controlled study[J].BMC Cancer,2014,14(14):22.
[3] Siegel RL,Miller KD,Jemal A. Cancer Statistics,2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[4]Dagogo-Jack I,Shaw AT. Tumour heterogeneity and resistance to cancer therapies[J].Nat Rev Clin Oncol,2018,15(2):81-94.
[5]Morgan RJ,Armstrong DK,Alvarez RD,et al.Ovarian cancer,version1. 2016,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2016,14(9):1134-1163.
[6]Cortazar P,Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer[J].J Clin Oncol,1999,17(5):1625-31.
[7]Zhang JIN,LI HX.Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay[J].Oncol Lett,2015,9(5):2374-2380.
[8]Richard S,Wells A,Connor J,et al.Use of ChemoFx for Identification of Effective Treatments in Epithelial Ovarian Cancer[J].PLoS Curr,2015,13:7.
[9]Hoffman RM,Vescio RA.Development of the Histoculture Drug Response Assay(HDRA)[J].Methods Mol Biol,2018,1760:39-48.
[10]崔颖,周丹,李叶,等.88例卵巢上皮性癌行ATP-TCA体外药敏试验结果分析[J].中国细胞生物学学报,2014,36(7):989-993.
[11]Fruehauf JP,Alberts DS.In vitro drug resistance versus chemosensitivity:two sides of different coins[J]. J Clin Oncol,2005,23(15):3641-3643.
[2]Van de laar R,Zusterzeel PL,Vangorp TA,et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer(SOCceR trial):a multicenter randomised controlled study[J].BMC Cancer,2014,14(14):22.
[3] Siegel RL,Miller KD,Jemal A. Cancer Statistics,2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[4]Dagogo-Jack I,Shaw AT. Tumour heterogeneity and resistance to cancer therapies[J].Nat Rev Clin Oncol,2018,15(2):81-94.
[5]Morgan RJ,Armstrong DK,Alvarez RD,et al.Ovarian cancer,version1. 2016,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2016,14(9):1134-1163.
[6]Cortazar P,Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer[J].J Clin Oncol,1999,17(5):1625-31.
[7]Zhang JIN,LI HX.Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay[J].Oncol Lett,2015,9(5):2374-2380.
[8]Richard S,Wells A,Connor J,et al.Use of ChemoFx for Identification of Effective Treatments in Epithelial Ovarian Cancer[J].PLoS Curr,2015,13:7.
[9]Hoffman RM,Vescio RA.Development of the Histoculture Drug Response Assay(HDRA)[J].Methods Mol Biol,2018,1760:39-48.
[10]崔颖,周丹,李叶,等.88例卵巢上皮性癌行ATP-TCA体外药敏试验结果分析[J].中国细胞生物学学报,2014,36(7):989-993.
[11]Fruehauf JP,Alberts DS.In vitro drug resistance versus chemosensitivity:two sides of different coins[J]. J Clin Oncol,2005,23(15):3641-3643.